﻿<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Explor Cardiol</journal-id>
<journal-id journal-id-type="publisher-id">EC</journal-id>
<journal-title-group>
<journal-title>Exploration of Cardiology</journal-title>
</journal-title-group>
<issn pub-type="epub">2994-5526</issn>
<publisher>
<publisher-name>Open Exploration Publishing</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.37349/ec.2024.00017</article-id>
<article-id pub-id-type="manuscript">101217</article-id>
<article-categories>
<subj-group>
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Feasibility of coronary flow velocity reserve during semi-supine exercise echocardiography: a single center study of 3,014 patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9085-4872</contrib-id>
<name>
<surname>Zagatina</surname>
<given-names>Angela</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-2010-1369</contrib-id>
<name>
<surname>Hanjykova</surname>
<given-names>Ogulleyla</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-2353-8468</contrib-id>
<name>
<surname>Petrova</surname>
<given-names>Ekaterina</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-8967-4605</contrib-id>
<name>
<surname>Begidova</surname>
<given-names>Irina</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4007-3322</contrib-id>
<name>
<surname>Kalinina</surname>
<given-names>Elena</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing—original draft</role>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing—review &amp; editing</role>
<role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="editor">
<name>
<surname>Das</surname>
<given-names>Undurti</given-names>
</name>
<role>Academic Editor</role>
<aff>Sri Ramachandra Medical University, India</aff>
</contrib>
</contrib-group>
<aff id="I1">
<sup>1</sup>Cardiology Department, Research Cardiology Center “Medika”, 197110 St. Petersburg, Russian Federation</aff>
<aff id="I2">
<sup>2</sup>Functional Diagnostic Department, Hospital “Railway-Medicine”, 192007 St. Petersburg, Russian Federation</aff>
<author-notes>
<corresp id="cor1">
<bold>
<sup>*</sup>Correspondence:</bold> Angela Zagatina, Cardiology Department, Research Cardiology Center “Medika”, 197110 St. Petersburg, Russian Federation. <email>zag_angel@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>04</day>
<month>02</month>
<year>2024</year>
</pub-date>
<volume>2</volume>
<issue>1</issue>
<fpage>9</fpage>
<lpage>18</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>11</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>04</day>
<month>01</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2024.</copyright-statement>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Aim:</title>
<p>There is a lack of studies that analyzed factors influencing on feasibility of coronary flow velocity reserve (CFVR) during exercise stress echocardiography (SE). The aim of the study was to define the feasibility of assessment of CFVR during exercise through SE depending on experience, techniques, and clinical factors.</p>
</sec>
<sec>
<title>Methods:</title>
<p>This is a single-center study. SE was performed using three generations of echo systems in five consecutive cohorts of patients by experienced and novice specialists. All patients performed a supine bicycle testing. CFVR was calculated in the middle/middle-distal parts of the left anterior descending artery (LAD). Three different adjustment settings were used for LAD visualization.</p>
</sec>
<sec>
<title>Results:</title>
<p>The study included 3,014 patients (59 years old ± 11 years old, 54% males). Age [odds ratio (OR) 0.98, 95% confidence interval (CI) 0.96–0.99, <italic>P</italic> &lt; 0.01], body mass index (BMI; OR 0.95, 95% CI 0.91–0.98, <italic>P</italic> &lt; 0.003), rest heart rate (OR 0.98, 95% CI 0.97–0.99, <italic>P</italic> &lt; 0.0005) and doctor’s experience (OR 2.7, 95% CI 1.57–4.53, <italic>P</italic> &lt; 0.0003) were independent factors that influence on feasibility. The feasibility of CFVR assessment during exercise SE in the whole population by experienced doctors was 89.4%. The feasibility of CFVR assessment of LAD in obese patients performed by experienced doctors using modern echo machines and new techniques was high (86.0%).</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>Coronary artery velocity reserve during supine exercise SE is a feasible, non-invasive available tool. The new generation echo machine and the new techniques provide a good feasibility of CFVR assessment, even in novice doctors. Despite a lower level of possibility to assess CFVR in obese patients or with a higher resting heart rate, this method is feasible in a great majority of such patients.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Coronary flow reserve</kwd>
<kwd>exercise stress echo</kwd>
<kwd>exercise coronary reserve</kwd>
<kwd>coronary artery ultrasound</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p id="p-1">Stress echocardiography (SE) is a great part of patients’ examination in chronic coronary syndromes and beyond coronary artery disease (CAD). Exercise stress tests are the only true physiological test and by far the safest. Thus, if the patient is able to exercise, then exercise stress is considered the test of choice [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. A lot of pilot and multicenter studies have proved an independent prognostic and diagnostic value of coronary flow velocity reserve (CFVR) in the left anterior descending artery (LAD) during SE [<xref ref-type="bibr" rid="B3">3</xref>–<xref ref-type="bibr" rid="B8">8</xref>]. The finding supports recent recommendations that coronary flow reserve should be measured more routinely in clinical practice [<xref ref-type="bibr" rid="B2">2</xref>]. Until recently it was considered that CFVR could be measured only in pharmacological tests. The recent multicenter study proved the feasibility of CFVR measuring during all types of SE [<xref ref-type="bibr" rid="B9">9</xref>], also matching data with the adverse outcome. However, there is a lack of studies that analyzed factors influencing this feasibility. The aim of the study was to define the feasibility of assessment of CFVR during exercise through SE depending on experience, techniques and clinical factors.</p>
</sec>
<sec id="s2">
<title>Materials and methods</title>
<sec id="t2-1">
<title>Study population/analyzed groups</title>
<p id="p-2">This is a single-center study included 3,014 patients. The inclusion criteria were that all the consecutive patients referred to SE for diagnostic/prognostic aims, as a clinical decision made by their doctors, and as well as their willingness to give their written informed consent to allow the scientific utilization of observational data, abiding respectfully to their privacy rights. All the phases of these studies were approved by the local ethical committees. There were five cohort of consecutive patients.</p>
<sec id="t2-1-1">
<title>Group 1</title>
<p id="p-3">Novice specialists with the “old coronary flow visualization” technique performed SE using an old generation echocardiography system (OGES). The patients were recruited from November 2011 to September 2012.</p>
</sec>
<sec id="t2-1-2">
<title>Group 2</title>
<p id="p-4">Experienced specialists with the “old coronary flow visualization” technique performed SE in group 2 using OGES. The patients were recruited from March 2015 to December 2017.</p>
</sec>
<sec id="t2-1-3">
<title>Group 3</title>
<p id="p-5">Experienced specialists with the “old coronary flow visualization” technique performed SE in group 3 using a new generation echocardiography system (NGES). The patients were recruited from February 2018 to December 2021.</p>
</sec>
<sec id="t2-1-4">
<title>Group 4</title>
<p id="p-6">Experienced specialists with the “new coronary flow visualization” technique performed SE in group 4 using NGES. The patients were recruited from September 2022 to July 2023.</p>
</sec>
<sec id="t2-1-5">
<title>Group 5</title>
<p id="p-7">A novice specialist with the “new coronary flow visualization” technique performed SE in group 5 using NGES. The patients were recruited from September 2022 to July 2023.</p>
<p id="p-8">A specialist is considered to be a “Novice” if he/she has performed less than 500 SE tests with CFVR or having less than 1 year of practice.</p>
<p id="p-9">A specialist is considered to be “Experienced” if he/she has performed more than 500 SE tests with CFVR whilst having more than 1 year of practice.</p>
<p id="p-10">GE Vivid 7 Dimension ultrasound system (GE Healthcare, Liestal, Switzerland) was defined in the study as an OGES. GE Vivid 9 (GE Healthcare, USA, manufactured in Horten, Norway), Vivid E95 (GE Healthcare, USA, manufactured in Horten, Norway) were defined as a NGES.</p>
<p id="p-11">“Old coronary flow visualization” was defined as if it used only coronary preset on ultrasound system. The “new technique” was defined as it was described in section coronary artery flow visualization. The groups 1, 2, 3 and 4 were examined by the same doctors.</p>
</sec>
</sec>
<sec id="t2-2">
<title>SE</title>
<p id="p-12">SE was performed according to previous and current guidelines as previously detailed [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B10">10</xref>]. We used commercially available ultrasound machines:</p>
<p id="p-13">
<list list-type="simple">
<list-item>
<label>(1)</label>
<p>GE Vivid 7 Dimension connected to a standard M4S transthoracic transducer.</p>
</list-item>
<list-item>
<label>(2)</label>
<p>GE Vivid E9 connected to a standard M5S transthoracic transducer.</p>
</list-item>
<list-item>
<label>(3)</label>
<p>GE Vivid E95 connected to a standard M5S transthoracic transducer.</p>
</list-item>
</list>
</p>
<p id="p-14">All patients performed a supine bicycle testing with the conventional visual assessment of wall motion abnormalities using e-Bike EL&amp;BP (General Electric, USA). The initial power output was 50 W, followed by increases of 25 W every 2 min until standard endpoints were reached. Electrocardiogram (ECG) and arterial pressure were monitored during the test. All studies were continuously recorded on digital video disc (DVD), internal and external hard-drives for off-line analysis.</p>
<p id="p-15">Images were obtained in the apical four- and two-chamber views, and the long- and short-axis parasternal views. Echocardiographic images were acquired at rest and at the peak of exercise. Post-stress images, analogous to those at rest, were obtained as soon as possible after stopping the exercise, and not later than 60 s. The images at rest, during stress and after stopping were compared side by side in a cine-loop display. Anti-anginal drugs were usually suspended before testing.</p>
</sec>
<sec id="t2-3">
<title>Coronary flow visualization</title>
<p id="p-16">CFVR was calculated in the middle/middle-distal parts of the LAD. The LAD was examined from a low left parasternal position to a modified apical two-, four-, or five-chamber positions at varying levels using views in the anterior interventricular groove. Examination of the anatomical course of the coronary arteries was performed using color Doppler mapping. The ultrasound beam was aligned parallel to the vessel flow as much as possible. There were two similar approaches for coronary flow color Doppler visualization.</p>
<sec id="t2-3-1">
<title>Old coronary flow visualization technique</title>
<p id="p-17">We used only the manufacturer preset “Coronary” with the embedded system settings. The velocity scale of color Doppler usually was set to 0.23–0.41 m/s at rest and the peak of exercise. Pulsed wave Doppler registered blood flow velocity patterns using a sample volume (2.0–3.0 mm) placed on the color signal (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p>
<fig id="fig1" position="float">
<label>Figure 1</label>
<caption>
<p>Three types of adjustment settings. A. The manufacturer preset “Coronary” with the embedded system settings. The velocity scale of color Doppler usually was set to 0.26 m/s; B. “Coronary” preset, color flow Doppler, modified two-dimensional (2D) mode to reduce the frequency, the “tissue priority” was adjusted to zero, the velocity scale of Nyquist limit was set to 0.20; C. “Cardiac” preset modification, color flow Doppler with decreased depth, Nyquist limit was adjusted to 0.23, “tissue priority” was reduced to zero. Red arrows point the time of diastolic coronary flow, near ECG P-waves. Red arrows: the time of recording coincides with a P-wave on ECG</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ec-02-101217-g001.tif" />
</fig>
</sec>
<sec id="t2-3-2">
<title>New coronary flow visualization technique</title>
<p id="p-18">If the standard “Coronary” preset could not provide optimal visualization, we used some special setting modifications to apply a better acquisition.</p>
<p id="p-19">In order to visualize a longer length of LAD, we used a different scheme:</p>
<p id="p-20">
<list list-type="simple">
<list-item>
<label>(1)</label>
<p>Switch “Coronary” preset.</p>
</list-item>
<list-item>
<label>(2)</label>
<p>Switch color flow Doppler.</p>
</list-item>
<list-item>
<label>(3)</label>
<p>Modify 2D mode to down frequency.</p>
</list-item>
<list-item>
<label>(4)</label>
<p>Down “tissue priority” to zero “0”.</p>
</list-item>
<list-item>
<label>(5)</label>
<p>Down velocity scale of Nyquist limit to 0.15–0.25 m/s adjusting the optimal visualization (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p>
</list-item>
</list>
</p>
<p id="p-21">If this scheme could not provide the optimal view. We used the standard manufactured “Cardiac” preset modification:</p>
<p id="p-22">
<list list-type="simple">
<list-item>
<label>(1)</label>
<p>Switch “Cardiac” preset.</p>
</list-item>
<list-item>
<label>(2)</label>
<p>Switch color flow Doppler.</p>
</list-item>
<list-item>
<label>(3)</label>
<p>Decrease the depth.</p>
</list-item>
<list-item>
<label>(4)</label>
<p>Modify Nyquist limit to 0.2–0.23 m/s.</p>
</list-item>
<list-item>
<label>(5)</label>
<p>Down “tissue priority” to zero “0” (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p>
</list-item>
</list>
</p>
<p id="p-23">To identify coronary artery flow we use the profile of flow, that was diastolic predominant. The time of the maximal velocity in sinus rhythm was observed nearly P-wave on ECG (red arrows, <xref ref-type="fig" rid="fig1">Figure 1</xref>).</p>
</sec>
</sec>
<sec id="t2-4">
<title>Coronary artery flow velocity reserve assessment</title>
<p id="p-24">Coronary flow Doppler images were acquired before and during exercise in the same part of the artery without moving the hand or with slight adjustment till just before the peak of exercise. If it was necessary to acquire the different parameters or loops with wall motion, we nearly visualized the same section of LAD after acquiring. The diastolic peaks of coronary flow velocities were measured (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The ratio of peak stress velocity to rest velocity was calculated as a CFVR. We consider the study to be technically successful if the Doppler signal could be registered till the peak of exercise.</p>
<fig id="fig2" position="float">
<label>Figure 2</label>
<caption>
<p>Measuring of coronary flow diastolic velocity</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ec-02-101217-g002.tif" />
</fig>
</sec>
<sec id="t2-5">
<title>Statistical analysis</title>
<p id="p-25">Continuous data are expressed as mean ± standard deviation or median (lower-upper quartile) depending on variable distribution, categorical data is expressed in percentages. A comparison of proportions was performed with Pearson’s Chi-square (<italic>χ<sup>2</sup></italic>) test and Fisher’s exact test, as appropriate. Continuous variables were compared by paired-samples <italic>t</italic>-test. The following categorical and continuous data were accounted for in the regression analysis: age, sex, body mass index (BMI), presence of arterial hypertension, diabetes mellitus, left bundle branch block (LBBB), previous myocardial infarction (MI), previous percutaneous coronary intervention (PCI), previous coronary bypass surgery, heart rate, blood pressure, exercise capacity, doctor’s experience, ejection fraction (EF), presence of ischemia during SE. A significance of 0.05 was required for a variable to be included in the multivariate model. Hazard ratio (HR) with the corresponding 95% confidence interval (CI) were estimated. <italic>P</italic> &lt; 0.05 was considered statistically significant. The Statistica statistical package version 12.0 (Stat Soft Inc., Tulsa, Oklahoma, USA) and MedCalc Statistical Software version 14.8.1 (MedCalc Software bvba, Ostend, Belgium) were used for statistical analysis.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<sec id="t3-1">
<title>Patient cohorts</title>
<p id="p-26">The main clinical characteristics, exercise, echocardiography parameters and LAD velocity data of the 3,014 study patients are described in <xref ref-type="table" rid="t1">Table 1</xref>. The patients were referred to SE with known (1,077 patients, 36%) or suspected CAD (1,937 patients, 64%).</p>
<table-wrap id="t1">
<label>Table 1</label>
<caption>
<p>Patients’ clinical, echocardiography, SE and coronary flow velocity characteristics</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
<bold>Variables</bold>
</th>
<th>
<bold>Overall (<italic>n</italic> = 3,014)</bold>
</th>
<th>
<p>
<bold>Group 1</bold>
</p>
<p>
<bold>(<italic>n</italic> = 903)</bold>
</p>
</th>
<th>
<p>
<bold>Group 2</bold>
</p>
<p>
<bold>(<italic>n</italic> = 1,204)</bold>
</p>
</th>
<th>
<p>
<bold>Group 3</bold>
</p>
<p>
<bold>(<italic>n</italic> = 693)</bold>
</p>
</th>
<th>
<p>
<bold>Group 4</bold>
</p>
<p>
<bold>(<italic>n</italic> = 113)</bold>
</p>
</th>
<th>
<p>
<bold>Group 5</bold>
</p>
<p>
<bold>(<italic>n</italic> = 101)</bold>
</p>
</th>
<th>
<bold>
<italic>P</italic> value</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>59 ± 11</td>
<td>56 ± 9</td>
<td>59 ± 11</td>
<td>61 ± 11</td>
<td>60 ± 11</td>
<td>58 ± 13</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Male sex</td>
<td>1,651 (54.8%)</td>
<td>582 (64.4%)</td>
<td>599 (49.8%)</td>
<td>357 (51.5%)</td>
<td>65 (57.5%)</td>
<td>48 (47.5%)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>BSA (m<sup>2</sup>)</td>
<td>1.96 ± 0.21</td>
<td>1.98 ± 0.21</td>
<td>1.96 ± 0.20</td>
<td>1.96 ± 0.22</td>
<td>1.95 ± 0.23</td>
<td>1.93 ± 0.24</td>
<td>0.103</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>28.6 ± 4.5</td>
<td>28.9 ± 4.6</td>
<td>28.6 ± 4.6</td>
<td>28.6 ± 4.3</td>
<td>27.4 ± 3.9</td>
<td>27.8 ± 4.6</td>
<td>&lt; 0.006</td>
</tr>
<tr>
<td>Hypertension, <italic>n</italic> (%)</td>
<td>2,326 (77.2%)</td>
<td>717 (79.4%)</td>
<td>835 (69.4%)</td>
<td>600 (86.6%)</td>
<td>98 (86.7%)</td>
<td>76 (75.2%)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Diabetes, <italic>n</italic> (%)</td>
<td>389 (12.9%)</td>
<td>127 (14.1%)</td>
<td>134 (11.1%)</td>
<td>105 (15.2%)</td>
<td>13 (11.5%)</td>
<td>10 (9.9%)</td>
<td>0.090</td>
</tr>
<tr>
<td>LBBB, <italic>n</italic> (%)</td>
<td>130 (4.3%)</td>
<td>50 (5.5%)</td>
<td>40 (3.3%)</td>
<td>31 (4.4%)</td>
<td>7 (6.2%)</td>
<td>2 (2.0%)</td>
<td>0.057</td>
</tr>
<tr>
<td>PCI, <italic>n</italic> (%)</td>
<td>587 (19.5%)</td>
<td>83 (9.2%)</td>
<td>290 (24.1%)</td>
<td>169 (24.4%)</td>
<td>31 (27.4%)</td>
<td>14 (13.9%)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>CABG, <italic>n</italic> (%)</td>
<td>173 (5.7%)</td>
<td>31 (3.4%)</td>
<td>65 (5.4%)</td>
<td>68 (9.8%)</td>
<td>8 (7.1%)</td>
<td>1 (1.0%)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Previous MI</td>
<td>838 (27.8%)</td>
<td>348 (38.5%)</td>
<td>282 (23.4%)</td>
<td>169 (24.4%)</td>
<td>23 (20.4%)</td>
<td>16 (15.8%)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>HtR (bpm) rest</td>
<td>72.5 ± 12.2</td>
<td>73.2 ± 12.6</td>
<td>71.6 ± 12.0</td>
<td>73.2 ± 12.5</td>
<td>70.5 ± 11.1</td>
<td>74.0 ± 12.4</td>
<td>&lt; 0.004</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>132.4 ± 17.3</td>
<td>132.5 ± 17.2</td>
<td>134.9 ± 17.4</td>
<td>128.8 ± 17.9</td>
<td>129.8 ± 12.8</td>
<td>129.9 ± 11.8</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>EF at rest (%)</td>
<td>63.0 ± 9.0</td>
<td>62.3 ± 11.2</td>
<td>63.9 ± 7.8</td>
<td>62.8 ± 8.5</td>
<td>61.9 ± 6.8</td>
<td>65.9 ± 7.4</td>
<td>&lt; 0.0004</td>
</tr>
<tr>
<td>AF during test, <italic>n</italic> (%)</td>
<td>96 (3.2%)</td>
<td>19 (2.1%)</td>
<td>35 (2.9%)</td>
<td>32 (4.6%)</td>
<td>5 (4.4%)</td>
<td>5 (5.0%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Exercise capscity, Wt</td>
<td>100 (75–125)</td>
<td>100 (75–150)</td>
<td>100 (75–125)</td>
<td>75 (75–125)</td>
<td>75 (50–125)</td>
<td>75 (50–125)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Ischemia, <italic>n</italic> (%)</td>
<td>1,546 (51.3%)</td>
<td>473 (52.4%)</td>
<td>646 (53.7%)</td>
<td>312 (45.0%)</td>
<td>55 (48.7%)</td>
<td>60 (59.4%)</td>
<td>&lt; 0.003</td>
</tr>
<tr>
<td>HtR (bpm) peak</td>
<td>125.8 ± 20.8</td>
<td>129.6 ± 20.3</td>
<td>124.7 ± 21.4</td>
<td>122.8 ± 20.3</td>
<td>121.9 ± 18.4</td>
<td>130.4 ± 19.2</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>LAD velocity at rest, cm/s</td>
<td>32.5 ± 13.0</td>
<td>34.7 ± 13.1</td>
<td>33.1 ± 13.3</td>
<td>29.7 ± 12.1</td>
<td>28.4 ± 9.4</td>
<td>31.7 ± 15.2</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>LAD velocity at peak, cm/s</td>
<td>61.3 ± 21.1</td>
<td>64.7 ± 25.3</td>
<td>62.6 ± 19.9</td>
<td>57.0 ± 19.2</td>
<td>54.7 ± 19.8</td>
<td>59.5 ± 11.8</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>CFVR</td>
<td>1.99 ± 0.67</td>
<td>1.94 ± 0.71</td>
<td>2.01 ± 0.68</td>
<td>2.00 ± 0.64</td>
<td>2.00 ± 0.51</td>
<td>2.09 ± 0.47</td>
<td>0.198</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>BSA: body surface area; CABG: coronary artery bypass surgery; HtR: heart rate; SBP: systolic blood pressure; AF: atrial fibrillation; Wt: watt</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p id="p-27">The achieved double product of heart rate and SBP were divided into quartiles. The CVFR increased significantly depending on the quartiles (1.51 ± 0.49 <italic>vs.</italic> 1.91 ± 0.58 <italic>vs.</italic> 2.26 ± 0.55 <italic>vs.</italic> 2.45 ± 0.50, <italic>P</italic> &lt; 0.0001, respectively).</p>
<p id="p-28">The prevalence of ischemia tests and CFVR obtained by novice <italic>vs.</italic> experienced operators were not significantly different: 53% <italic>vs.</italic> 51%, <italic>P</italic> = 0.17; 1.96 ± 0.68 <italic>vs.</italic> 2.00 ± 0.66, <italic>P</italic> = 0.12, respectively.</p>
<p id="p-29">The time spent on additional scanning of coronary artery flow before SE was approximately 60–90 s.</p>
</sec>
<sec id="t3-2">
<title>Feasibility</title>
<p id="p-30">The feasibility of CFVR assessment during exercise stress echo of the overall study population was 81.3%. Some examples of CFVR are in the <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p>
<fig id="fig3" position="float">
<label>Figure 3</label>
<caption>
<p>Examples of different CFVR. Matched pairs of patients with a low exercise capacity (A) and a medium exercise capacity (B) on the similar heart rate. Depressed (patients 1, 3) and normal (patients 2, 4) CFVR during exercise</p>
</caption>
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ec-02-101217-g003.tif" />
</fig>
<p id="p-31">Among all the above-mentioned parameters, age, BMI, resting heart rate and doctor’s experience were independent factors that influence on feasibility, <xref ref-type="table" rid="t2">Table 2</xref>.</p>
<table-wrap id="t2">
<label>Table 2</label>
<caption>
<p>Significant independent parameters influencing on feasibility of CFVR assessment</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
<bold>Variables</bold>
</th>
<th>
<bold>Odds ratio</bold>
</th>
<th>
<p>
<bold>Multivariate analysis</bold>
</p>
<p>
<bold>HR (95% CI)</bold>
</p>
</th>
<th>
<bold>
<italic>P</italic> value</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.9795</td>
<td>0.9643–0.9950</td>
<td>0.0096</td>
</tr>
<tr>
<td>BMI</td>
<td>0.9470</td>
<td>0.9137–0.9816</td>
<td>0.0029</td>
</tr>
<tr>
<td>Rest HtR</td>
<td>0.9779</td>
<td>0.9657–0.9902</td>
<td>0.0005</td>
</tr>
<tr>
<td>Doctor experience</td>
<td>2.6697</td>
<td>1.5735–4.5298</td>
<td>0.0003</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>HtR: heart rate</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p id="p-32">The differences between the groups feasibilities presented in <xref ref-type="table" rid="t3">Table 3</xref>. It was 65% <italic>vs.</italic> 89% (<italic>P</italic> &lt; 0.0001) for doctors who performed less than 500 SE tests and experience of less than 1 year, in comparison with doctors who performed more than 500 SE and a practice more than 1 year. The feasibility of CFVR LAD assessment in the whole population by experienced doctors was 89.4%.</p>
<table-wrap id="t3">
<label>Table 3</label>
<caption>
<p>The differences between the group feasibilities of CFVR assessment</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
<bold>Variables</bold>
</th>
<th>
<p>
<bold>Group 1</bold>
</p>
<p>
<bold>(<italic>n</italic> = 903)</bold>
</p>
</th>
<th>
<p>
<bold>Group 2</bold>
</p>
<p>
<bold>(<italic>n</italic> = 1,204)</bold>
</p>
</th>
<th>
<p>
<bold>Group 3</bold>
</p>
<p>
<bold>(<italic>n</italic> = 693)</bold>
</p>
</th>
<th>
<p>
<bold>Group 4</bold>
</p>
<p>
<bold>(<italic>n</italic> = 113)</bold>
</p>
</th>
<th>
<p>
<bold>Group 5</bold>
</p>
<p>
<bold>(<italic>n</italic> = 101)</bold>
</p>
</th>
<th>
<bold>
<italic>P</italic> value</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feasibility</td>
<td>63.5%</td>
<td>89.6%</td>
<td>88.7%</td>
<td>91.2%</td>
<td>76.2%</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Feasibility in obesity <italic>vs.</italic> not obese patients</td>
<td>61.9% <italic>vs.</italic> 65.0% (<italic>P</italic> = 0.36)</td>
<td>86.5% <italic>vs.</italic> 91.3% (<italic>P</italic> &lt; 0.01)</td>
<td>86.2% <italic>vs.</italic> 90.2% (<italic>P</italic> = 0.11)</td>
<td>84.4% <italic>vs.</italic> 93.0% (<italic>P</italic> = 0.11)</td>
<td>65.5% <italic>vs.</italic> 80.6% (<italic>P</italic> = 0.11)</td>
<td>-</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Group 1 <italic>vs.</italic> group 2, <italic>P</italic> &lt; 0.0001; group 2 <italic>vs.</italic> group 3, <italic>P</italic> = 0.55; group 3 <italic>vs.</italic> group 4, <italic>P</italic> = 0.44; group 4 <italic>vs.</italic> group 5, <italic>P</italic> &lt; 0.003; group 1 <italic>vs.</italic> group 5, <italic>P</italic> &lt; 0.02. -: blank cell</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p id="p-33">The feasibility of CFVR assessment of LAD in obese patients performed by experienced doctors was 86.0% using NGES.</p>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p id="p-34">This study has shown that the assessment of CFVR during supine bicycle exercise tests is a highly feasible method. Indeed, most SE can be added by measuring of coronary flow velocity even in cases when the doctor is a newcomer. If the doctor has experience in conducting more than 500 tests with coronary flow assessment and has more than 1 year of practice, the feasibility of this method is near 90% even with the old generation echo systems. The new techniques and new generation echo systems made the visualization of coronary artery simpler and more accessible. The use of multifrequency matrix single crystal phased array probe transducers with second tissue harmonics provide an estimation of both distal and proximal-mid LAD parts. The new manufacturer presets help to ease the coronary artery visualization. It plays a crucial role in training doctors. In the study there is a significant difference between feasibility for novice doctors with using the new techniques.</p>
<p id="p-35">The aim of CFVR assessment was proved in a large number of studies including pilot and multicenter ones [<xref ref-type="bibr" rid="B3">3</xref>–<xref ref-type="bibr" rid="B9">9</xref>]. It was found that, across a broad range of pathologies and patient cohorts, an impaired CFR was associated with an increased hazard of all-cause mortality and major adverse cardiovascular events [<xref ref-type="bibr" rid="B11">11</xref>].</p>
<p id="p-36">First, it was demonstrated for pharmacological tests. Indeed, the CFVR is independent, one of the major diagnostic and prognostic parameters during stress tests. However, the exercise stress tests are considered more physiological than pharmacological stress tests and include the prognostically important finding of the patient’s exercise capacity. According to current guidelines, if a patient can exercise, this should be the preferred stress modality [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. The Feasibility of CFVR assessment during exercise was demonstrated, first, in a pilot study [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>] in 2016, then in a multicenter study, proving its diagnostic and prognostic values [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>]. Currently, the CFVR is an essential valuable independent parameter, evaluated during all types of SE. Now it is an integral part of the modern ABCDE protocol [<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B14">14</xref>]. We did not find papers in literature on the direct comparison of CFVR values obtained through different exercise and pharmacological stressors in the same patients. Previously single and multicenter studies had shown that CFVR in LAD can be obtained during all forms of SE protocols, but the feasibility is significantly higher with rapid cardiac pacing and pharmacological tests as compared with exercises [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B15">15</xref>]. However, exercise CFVR assessment was achievable for the majority of patients. Besides, it is possible to repeat the test through other attempts of CFVR evaluation, knowing its safe useful physiologic nature.</p>
<p id="p-37">The main factors that influence on feasibility were age, BMI, resting heart rate and doctor’s experience. Previously the sceptics doubted in possibility of CFVR assessment in obese patients generally. Takeuchi and co-authors [<xref ref-type="bibr" rid="B16">16</xref>] had demonstrated that the noninvasive measurement of CFVR during SE was feasible (92%) even in a relatively obese population with high and low frequencies of obesity. Their study had shown to measure CFVR for obese patient during pharmacologic SE. Our study also confirmed a possibility of this assessment during exercise, although with a lower feasibility. The new generation of echo machines help to achieve a good coronary artery visualization during exercise tests in obese patients. Despite the influences of BMI on coronary artery visualization, it is possible in a great majority of patients that the feasibility of CFVR assessment is approximately 86% for experienced doctors. The resting heart rate is also a known factor that influences the coronary artery flow assessment [<xref ref-type="bibr" rid="B17">17</xref>]. It is connected with a shorter diastole, when the main coronary flow is better visualized. However, this method is feasible in a great majority of patients with more higher heart rate also.</p>
<p id="p-38">Understanding the difficulties of coronary artery visualization in patients during exercise, we consider that 500 exams conducted by an echocardiographer to be the minimal level of experience. Earlier, a one year-experience was considered adequate. However, the new generation echo systems with developed methods of coronary artery visualization provide a good feasibility of CFVR assessment in novice specialists even during the first 100 exams.</p>
<sec id="t4-1">
<title>Limitations</title>
<p id="p-39">This is a single center study with cohorts of different periods. The study population consisted of five consecutive patient cohorts, there was a high prevalence of ischemic tests in these cohorts.</p>
<p id="p-40">Groups 4 and 5 had a smaller number of patients that could influence to <italic>P</italic> value between subgroups of patients with and without obesity. There was not the whole information about smoking status to analyze its influence on feasibility and optimal techniques for coronary flow assessment. We had no coronary angiography data about LAD stenoses for the study cohorts. We did not compare the difference of the visualization methods between each other.</p>
<p id="p-41">In conclusion, coronary artery velocity reserve during supine exercise SE is a feasible, non-invasive and readily available tool. The new generation echo machine and the new techniques provide a good feasibility of CFVR assessment in novice doctors. Despite a lower level of possibility to assess CFVR in obese patients or in a higher resting heart rate, this method is feasible in a great majority of such patients. It suits for every day practice.</p>
</sec>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>BMI</term>
<def>
<p>body mass index</p>
</def>
</def-item>
<def-item>
<term>CFVR</term>
<def>
<p>coronary flow velocity reserve</p>
</def>
</def-item>
<def-item>
<term>CI</term>
<def>
<p>confidence interval</p>
</def>
</def-item>
<def-item>
<term>ECG</term>
<def>
<p>electrocardiogram</p>
</def>
</def-item>
<def-item>
<term>LAD</term>
<def>
<p>left anterior descending artery</p>
</def>
</def-item>
<def-item>
<term>NGES</term>
<def>
<p>new generation echocardiography system</p>
</def>
</def-item>
<def-item>
<term>OGES</term>
<def>
<p>old generation echocardiography system</p>
</def>
</def-item>
<def-item>
<term>OR</term>
<def>
<p>odds ratio</p>
</def>
</def-item>
<def-item>
<term>SBP</term>
<def>
<p>systolic blood pressure</p>
</def>
</def-item>
<def-item>
<term>SE</term>
<def>
<p>stress echocardiography</p>
</def>
</def-item>
</def-list>
</glossary>
<sec id="s5">
<title>Declarations</title>
<sec>
<title>Author contributions</title>
<p>AZ and OH: Conceptualization, Investigation, Writing—original draft, Writing—review &amp; editing, Supervision. EP and IB: Validation, Writing—review &amp; editing. EK: Investigation, Writing—original draft, Writing—review &amp; editing, Supervision. All authors read and approved the submitted version.</p>
</sec>
<sec sec-type="COI-statement">
<title>Conflicts of interest</title>
<p>The authors declare that they have no conflicts of interest.</p>
</sec>
<sec>
<title>Ethical approval</title>
<p>All the phases of these studies were approved by the local ethical committee of Research Cardiology Center “Medika”.</p>
</sec>
<sec>
<title>Consent to participate</title>
<p>Informed consent to participate in the study was obtained from all participants.</p>
</sec>
<sec>
<title>Consent to publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>The data supporting the results of the article can be obtained by directly contacting the corresponding author (<email>zag_angel@yahoo.com</email>).</p>
</sec>
<sec>
<title>Funding</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Copyright</title>
<p>© The Author(s) 2024.</p>
</sec>
</sec>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pellikka</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Arruda-Olson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chaudhry</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>TR</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the american society of echocardiography</article-title>
<source>J Am Soc Echocardiogr</source>
<year iso-8601-date="2020">2020</year>
<volume>33</volume>
<fpage>1</fpage>
<lpage>41.e8</lpage>
<pub-id pub-id-type="doi">10.1016/j.echo.2019.07.001</pub-id>
<pub-id pub-id-type="pmid">31740370</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pierard</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Peteiro</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Djordjevic-Dikic</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sade</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Cortigiani</surname>
<given-names>L</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>The clinical use of stress echocardiography in chronic coronary syndromes and beyond coronary artery disease: a clinical consensus statement from the European Association of Cardiovascular Imaging of the ESC</article-title>
<source>Eur Heart J Cardiovasc Imaging</source>
<year iso-8601-date="2024">2024</year>
<volume>25</volume>
<fpage>e65</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1093/ehjci/jead250</pub-id>
<pub-id pub-id-type="pmid">37798126</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rigo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cortigiani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pasanisi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Richieri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cutaia</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Celestre</surname>
<given-names>M</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>The additional prognostic value of coronary flow reserve on left anterior descending artery in patients with negative stress echo by wall motion criteria. A transthoracic vasodilator stress echocardiography study</article-title>
<source>Am Heart J</source>
<year iso-8601-date="2006">2006</year>
<volume>151</volume>
<fpage>124</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.ahj.2005.03.008</pub-id>
<pub-id pub-id-type="pmid">16368303</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortigiani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rigo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gherardi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bovenzi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Molinaro</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Picano</surname>
<given-names>E</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Coronary flow reserve during dipyridamole stress echocardiography predicts mortality</article-title>
<source>JACC Cardiovasc Imaging</source>
<year iso-8601-date="2012">2012</year>
<volume>5</volume>
<fpage>1079</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1016/j.jcmg.2012.08.007</pub-id>
<pub-id pub-id-type="pmid">23153906</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Djordjevic</surname>
<given-names>Dikic A</given-names>
</name>
<name>
<surname>Tesic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Boskovic</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Giga</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Stepanovic</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Petrovic</surname>
<given-names>M</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Prognostic value of preserved coronary flow velocity reserve by noninvasive transthoracic Doppler echocardiography in patients with angiographically intermediate left main stenosis</article-title>
<source>J Am Soc Echocardiogr</source>
<year iso-8601-date="2019">2019</year>
<volume>32</volume>
<fpage>74</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1016/j.echo.2018.09.020</pub-id>
<pub-id pub-id-type="pmid">30459120</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortigiani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ciampi</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lombardo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rigo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bovenzi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Picano</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Age- and gender-specific prognostic cutoff values of coronary flow velocity reserve in vasodilator stress echocardiography</article-title>
<source>J Am Soc Echocardiogr</source>
<year iso-8601-date="2019">2019</year>
<volume>32</volume>
<fpage>1307</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.echo.2019.05.020</pub-id>
<pub-id pub-id-type="pmid">31377069</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schroder</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Michelsen</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Mygind</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Suhrs</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Bove</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Bechsgaard</surname>
<given-names>DF</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study</article-title>
<source>Eur Heart J</source>
<year iso-8601-date="2021">2021</year>
<volume>42</volume>
<fpage>228</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehaa944</pub-id>
<pub-id pub-id-type="pmid">33477168</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciampi</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zagatina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cortigiani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wierzbowska-Drabik</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kasprzak</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Haberka</surname>
<given-names>M</given-names>
</name>
<etal>et al.</etal>
</person-group>
<article-title>Prognostic value of stress echocardiography assessed by the ABCDE protocol</article-title>
<source>Eur Heart J</source>
<year iso-8601-date="2021">2021</year>
<volume>42</volume>
<fpage>3869</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehab493</pub-id>
<pub-id pub-id-type="pmid">34449837</pub-id>
<pub-id pub-id-type="pmcid">PMC8486488</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciampi</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zagatina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cortigiani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gaibazzi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Borguezan</surname>
<given-names>Daros C</given-names>
</name>
<name>
<surname>Zhuravskaya</surname>
<given-names>N</given-names>
</name>
<etal>et al.</etal>
<collab>Stress Echo 2020 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging</collab>
</person-group>
<article-title>Functional, anatomical, and prognostic correlates of coronary flow velocity reserve during stress echocardiography</article-title>
<source>J Am Coll Cardiol</source>
<year iso-8601-date="2019">2019</year>
<volume>74</volume>
<fpage>2278</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2019.08.1046</pub-id>
<pub-id pub-id-type="pmid">31672185</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sicari</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nihoyannopoulos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kasprzak</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lancellotti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Poldermans</surname>
<given-names>D</given-names>
</name>
<etal>et al.</etal>
<collab>European Association of Echocardiography</collab>
</person-group>
<article-title>Stress echocardiography expert consensus statement—executive summary: European Association of Echocardiography (EAE) (a registered branch of the ESC)</article-title>
<source>Eur Heart J</source>
<year iso-8601-date="2009">2009</year>
<volume>30</volume>
<fpage>278</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehn492</pub-id>
<pub-id pub-id-type="pmid">19001473</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelshiker</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Seligman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Foley</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nowbar</surname>
<given-names>AN</given-names>
</name>
<etal>et al.</etal>
<collab>Coronary Flow Outcomes Reviewing Committee</collab>
</person-group>
<article-title>Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis</article-title>
<source>Eur Heart J</source>
<year iso-8601-date="2022">2022</year>
<volume>43</volume>
<fpage>1582</fpage>
<lpage>93</lpage>
<comment>Erratum in: Eur Heart J. 2023;44:27. </comment>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehab775</pub-id>
<pub-id pub-id-type="pmid">34849697</pub-id>
<pub-id pub-id-type="pmcid">PMC9020988</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zagatina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhuravskaya</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Egom</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kovacova</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kruzliak</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>A novel method for left anterior coronary artery flow velocity assessment by transthoracic echocardiography at the peak of a supine bicycle test</article-title>
<source>Acta Radiol</source>
<year iso-8601-date="2016">2016</year>
<volume>57</volume>
<fpage>1056</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="doi">10.1177/0284185115617350</pub-id>
<pub-id pub-id-type="pmid">26676763</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zagatina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhuravskaya</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>The additive prognostic value of coronary flow velocity reserve during exercise echocardiography</article-title>
<source>Eur Heart J Cardiovasc Imaging</source>
<year iso-8601-date="2017">2017</year>
<volume>18</volume>
<fpage>1179</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="doi">10.1093/ehjci/jew164</pub-id>
<pub-id pub-id-type="pmid">27502295</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zagatina</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wierzbowska-Drabik</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Borguezan</surname>
<given-names>Daros C</given-names>
</name>
<name>
<surname>D'Andrea</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ciampi</surname>
<given-names>Q</given-names>
</name>
</person-group>
<article-title>Sustainability and versatility of the ABCDE protocol for stress echocardiography</article-title>
<source>J Clin Med</source>
<year iso-8601-date="2020">2020</year>
<volume>9</volume>
<elocation-id>3184</elocation-id>
<pub-id pub-id-type="doi">10.3390/jcm9103184</pub-id>
<pub-id pub-id-type="pmid">33008112</pub-id>
<pub-id pub-id-type="pmcid">PMC7601661</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wierzbowska-Drabik</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Picano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cortigiani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kasprzak</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Comparison of coronary flow reserve feasibility in different stress echocardiography protocols: dobutamine, dipyridamole, exercise, and rapid pacing</article-title>
<source>Pol Arch Intern Med</source>
<year iso-8601-date="2021">2021</year>
<volume>131</volume>
<fpage>830</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.20452/pamw.16035</pub-id>
<pub-id pub-id-type="pmid">34142788</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takeuchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lodato</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Furlong</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Feasibility of measuring coronary flow velocity and reserve in the left anterior descending coronary artery by transthoracic Doppler echocardiography in a relatively obese american population</article-title>
<source>Echocardiography</source>
<year iso-8601-date="2005">2005</year>
<volume>22</volume>
<fpage>225</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1111/j.0742-2822.2005.04004.x</pub-id>
<pub-id pub-id-type="pmid">15725157</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caiati</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pollice</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lepera</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Heart rate lowering significantly increases feasibility in Doppler recording blood flow velocity in coronaries during transthoracic Doppler echocardiography</article-title>
<source>Diagnostics (Basel)</source>
<year iso-8601-date="2023">2023</year>
<volume>13</volume>
<elocation-id>670</elocation-id>
<pub-id pub-id-type="doi">10.3390/diagnostics13040670</pub-id>
<pub-id pub-id-type="pmid">36832158</pub-id>
<pub-id pub-id-type="pmcid">PMC9955744</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>